Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

Michael J Hochman; Gloria F Gerber; Philip H Imus; Syed Abbas Ali; Amy E DeZern

doi:10.1016/j.lrr.2024.100469

Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

Leuk Res Rep. 2024 Jul 9:22:100469. doi: 10.1016/j.lrr.2024.100469. eCollection 2024.

Authors

Michael J Hochman^{1

2}, Gloria F Gerber², Philip H Imus¹, Syed Abbas Ali¹, Amy E DeZern¹

Affiliations

¹ Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States.
² Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, United States.

Abstract

Both clonal plasma cell and myeloid disorders occur more frequently with age. Patients with concurrent clonal plasma cell and myeloid disorders (CPCMD) can present clinical and therapeutic challenges. In this single-institution cohort of patients with CPCMD (n = 18), we abstracted clinically relevant themes. A majority of patients (12/18) were treated with clone-directed therapies and three received treatment targeting both clones. Treatment of clones with targetable genetic lesions or those causing end-organ complications should be prioritized. Simultaneous treatment of both clones can be safe but is best done in a stepwise manner. Further study of patients with dual clonal processes is warranted.

Keywords: Malignancy precursors; Monoclonal gammopathies; Myelodysplastic syndrome; dual hematologic disorders.

Publication types

Case Reports

Grants and funding

T32 HL007525/HL/NHLBI NIH HHS/United States